Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors

Nature Genetics

Volumn 49, Issue 5, 2017, Pages 789-794

  Melin, Beatrice S ^a   Barnholtz Sloan, Jill S ^b   Wrensch, Margaret R ^c,d   Johansen, Christoffer ^e,ah   Il'yasova, Dora ^f,g   Kinnersley, Ben ^h   Ostrom, Quinn T ^b   Labreche, Karim ^h,i   Chen, Yanwen ^b   Armstrong, Georgina ^j   Liu, Yanhong ^j   Eckel Passow, Jeanette E ^k   Decker, Paul A ^k   Labussière, Marianne ⁱ   Idbaih, Ahmed ^i,l   Hoang Xuan, Khe ^i,l   Di Stefano, Anna Luisa ^i,l   Mokhtari, Karima ^i,l   Delattre, Jean Yves ^i,l   Broderick, Peter ^h   Galan, Pilar ^m   Gousias, Konstantinos ⁿ   Schramm, Johannes ⁿ   Schoemaker, Minouk J ^h   Fleming, Sarah J ^o   Herms, Stefan ^o   Heilmann, Stefanie ^p   Nöthen, Markus M ^p   Wichmann, Heinz Erich ^q,r,s   Schreiber, Stefan ^t   Swerdlow, Anthony ^h   Lathrop, Mark ^u   Simon, Matthias ⁿ   Sanson, Marc ^i,l   Andersson, Ulrika ^a   Rajaraman, Preetha ^v   Chanock, Stephen ^v   Linet, Martha ^v   Wang, Zhaoming ^v   Yeager, Meredith ^v   Wiencke, John K ^c,d   Hansen, Helen ^c   McCoy, Lucie ^c   Rice, Terri ^c   Kosel, Matthew L ^k   Sicotte, Hugues ^k   Amos, Christopher I ^w   Bernstein, Jonine L ^x   Davis, Faith ^y   Lachance, Dan ^z   Lau, Ching ^j   Merrell, Ryan T ^aa   Shildkraut, Joellen ^g   Ali Osman, Francis ^g   Sadetzki, Siegal ^ab,ac   Scheurer, Michael ^j   Shete, Sanjay ^ad   Lai, Rose K ^ae   Claus, Elizabeth B ^af,ag   Olson, Sara H ^x   Jenkins, Robert B ^z   Houlston, Richard S ^h   Bondy, Melissa L ^j   Freeman, L E B ^v   Koutros, S ^v   Albanes, D ^v   Visvanathan, K ^ah,ai   Stevens, V L ^aj   Henriksson, R ^a   Michaud, D S ^ak   Feychting, M ^al   Ahlbom, A ^al   Giles, G G ^an,ao   Milne, R ^an,ao   McKean Cowdin, R ^ae   Le Marchand, L ^ap   Stampfer, M ^ag,aq   Ruder, A M ^ar   Carreon, T ^ar   Hallmans, G ^a   Zeleniuch Jacquotte, A ^as   Gaziano, J M ^at   Sesso, H D ^ag   Purdue, M P ^v   White, E ^am   Buring, J ^ag   more..

^a UMEÅ UNIVERSITY   (Sweden)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f GEORGIA STATE UNIVERSITY   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k Mayo Clinic College of Medicine   (United States)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^m UNIVERSITÉ PARIS 13   (France)

ⁿ UNIVERSITY HOSPITAL BONN   (Germany)

^o UNIVERSITY OF LEEDS   (United Kingdom)

^p UNIVERSITY OF BONN   (Germany)

^q INSTITUTE OF EPIDEMIOLOGY   (Germany)

^r UNIVERSITY OF MUNICH   (Germany)

^s TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^t UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^u MCGILL UNIVERSITY   (Canada)

^v NATIONAL CANCER INSTITUTE   (United States)

^w DARTMOUTH MEDICAL SCHOOL   (United States)

^x MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^y UNIVERSITY OF ALBERTA   (Canada)

^z MAYO CLINIC CANCER CENTER   (United States)

^aa NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^ab GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^ac TEL AVIV UNIVERSITY   (Israel)

^ad UNIVERSITY OF TEXAS   (United States)

^ae UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^af YALE UNIVERSITY   (United States)

^ag BRIGHAM AND WOMEN S HOSPITAL   (United States)

^ah JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^ai JOHNS HOPKINS UNIVERSITY   (United States)

^aj AMERICAN CANCER SOCIETY   (United States)

^ak TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^al KAROLINSKA INSTITUTE   (Sweden)

^am UNIVERSITY OF WASHINGTON   (United States)

^an CANCER EPIDEMIOLOGY CENTRE   (Australia)

^ao UNIVERSITY OF MELBOURNE   (Australia)

^ap UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^aq HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^ar NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^as NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^at VA BOSTON HEALTHCARE SYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN MDMX;

ARTICLE; BRAIN CORTEX; CANCER RISK; CELL IMMORTALIZATION; CEREBELLUM; CHROMOSOME 11Q; CHROMOSOME 16P; CHROMOSOME 22Q; CONTROLLED STUDY; DEREGULATION; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GLIOBLASTOMA; GLIOMA; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; NEURAL STEM CELL; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; TELOMERE; TELOMERE LENGTH; ALLELE; BRAIN TUMOR; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; META ANALYSIS (TOPIC); PROCEDURES;

ALLELES; BRAIN NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GLIOBLASTOMA; GLIOMA; HUMANS; META-ANALYSIS AS TOPIC; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI;

EID: 85016134775     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3823     Document Type: Article

References (76)

1. Bondy, M.L. et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 113, 1953-1968 (2008).
2. Ostrom, Q.T. et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-oncol. 17 (Suppl. 4), iv1-iv62 (2015).
3. Louis, D.N. et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 114, 97-109 (2007).
4. Ostrom, Q.T. et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-oncol. 16, iv1-iv63 (2014).
5. Ostrom, Q.T. et al. The epidemiology of glioma in adults: a 'state of the science' review. Neuro-oncol. 16, 896-913 (2014).
6. Hemminki, K., Tretli, S., Sundquist, J., Johannesen, T.B. & Granstrom, C. Familial risks in nervous-system tumors: a histology-specific analysis from Sweden and Norway. Lancet Oncol. 10, 481-488 (2009).
7. Sanson, M. et al. Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum. Mol. Genet. 20, 2897-2904 (2011).
8. Shete, S. et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat. Genet. 41, 899-904 (2009).
9. Wrensch, M. et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat. Genet. 41, 905-908 (2009).
10. Kinnersley, B. et al. Genome-wide association study identifies multiple susceptibility loci for glioma. Nat. Commun. 6, 8559 (2015).
11. Walsh, K.M. et al. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat. Genet. 46, 731-735 (2014).
12. Jenkins, R.B. et al. A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat. Genet. 44, 1122-1125 (2012).
13. Rajaraman, P. et al. Genome-wide association study of glioma and meta-analysis. Hum. Genet. 131, 1877-1888 (2012).
14. Stacey, S.N. et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat. Genet. 43, 1098-1103 (2011).
15. Kinnersley, B. et al. Quantifying the heritability of glioma using genome-wide complex trait analysis. Sci. Rep. 5, 17267 (2015).
16. Lonsdale, J. et al. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580-585 (2013).
17. Westra, H.J. et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet. 45, 1238-1243 (2013).
18. Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex-trait gene targets. Nat. Genet. 48, 481-487 (2016).
19. Andersson, R. et al. An atlas of active enhancers across human cell types and tissues. Nature 507, 455-461 (2014).
20. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934-947 (2013).
21. Ruark, E. et al. Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. Nat. Genet. 45, 686-689 (2013).
22. Wu, C. et al. Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. Nat. Genet. 44, 1090-1097 (2012).
23. Riemenschneider, M.J. et al. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res. 59, 6091-6096 (1999).
24. Boland, E. et al. Mapping of deletion and translocation breakpoints in 1q44 implicates the serine-threonine kinase AKT3 in postnatal microcephaly and agenesis of the corpus callosum. Am. J. Hum. Genet. 81, 292-303 (2007).
25. Turner, K.M. et al. Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proc. Natl. Acad. Sci. USA 112, 3421-3426 (2015).
26. Gur, G. et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 23, 3270-3281 (2004).
27. Yang, J.A. et al. LRIG1 enhances the radio-sensitivity of radio-resistant human glioblastoma U251 cells via attenuation of the EGFR-AKT signaling pathway. Int. J. Clin. Exp. Pathol. 8, 3580-3590 (2015).
28. Wei, J. et al. miR-20a mediates temozolomide resistance in glioblastoma cells via negatively regulating LRIG1 expression. Biomed. Pharmacother. 71, 112-118 (2015).
29. Watanabe, T., Nobusawa, S., Kleihues, P. & Ohgaki, H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 174, 1149-1153 (2009).
30. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
31. Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522 (2010).
32. Christensen, B.C. et al. DNA methylation, isocitrate dehydrogenase mutation and survival in glioma. J. Natl. Cancer Inst. 103, 143-153 (2011).
33. Sanson, M. et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 27, 4150-4154 (2009).
34. Eckel-Passow, J.E. et al. Glioma groups based on 1p/19q, IDH and TERT promoter mutations in tumors. N. Engl. J. Med. 372, 2499-2508 (2015).
35. Walsh, K.M. et al. Telomere maintenance and the etiology of adult glioma. Neuro-oncol. 17, 1445-1452 (2015).
36. Miyake, Y. et al. RPA-like mammalian Ctc1-Stn1-Ten1 complex binds to single-stranded DNA and protects telomeres independently of the Pot1 pathway. Mol. Cell 36, 193-206 (2009).
37. Chen, L.Y., Redon, S. & Lingner, J. The human CST complex is a terminator of telomerase activity. Nature 488, 540-544 (2012).
38. Bainbridge, M.N. et al. Germline mutations in shelterin complex genes are associated with familial glioma. J. Natl. Cancer Inst. 107, 384 (2014).
39. Zhang, C. et al. Genetic determinants of telomere length and risk of common cancers: a mendelian randomization study. Hum. Mol. Genet. 24, 5356-5366 (2015).
40. Walsh, K.M. et al. Longer genotypically estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget 6, 42468-42477 (2015).
41. Ceccarelli, M. et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164, 550-563 (2016).
42. Xipell, E. et al. Endoplasmic-reticulum-stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG and Rad51. Neuro-oncol. 18, 1109-1119 (2016).
43. Nicolas, C.S. et al. The role of JAK-STAT signaling within the CNS. JAK-STAT 2, e22925 (2013).
44. Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481-2498 (2015).
45. Hepworth, S.J. et al. Mobile phone use and risk of glioma in adults: case-control study. BMJ 332, 883-887 (2006).
46. Amirian, E.S. et al. The Glioma International Case-Control Study: a report from the Genetic Epidemiology of Glioma International Consortium. Am. J. Epidemiol. 183, 85-91 (2016).
47. Li, Y. et al. FastPop: a rapid principal component-derived method to infer intercontinental ancestry using genetic data. BMC Bioinformatics 17, 122 (2016).
48. Cardis, E. et al. The INTERPHONE study: design, epidemiological methods and description of the study population. Eur. J. Epidemiol. 22, 647-664 (2007).
49. Hercberg, S. et al. The SU.VI.MAX study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch. Intern. Med. 164, 2335-2342 (2004).
50. Wichmann, H.E., Gieger, C., Illig, T. & MONICA-KORA Study Group. KORA-gen-resource for population genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen 67 (Suppl. 1), S26-S30 (2005).
51. Krawczak, M. et al. PopGen: population-based recruitment of patients and controls for the analysis of complex genotype-phenotype relationships. Community Genet. 9, 55-61 (2006).
52. Schmermund, A. et al. Assessment of clinically silent atherosclerotic disease, and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL study. Risk factors, evaluation of coronary calcium and lifestyle. Am. Heart J. 144, 212-218 (2002).
53. Hunter, D.J. et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39, 870-874 (2007).
54. Yeager, M. et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39, 645-649 (2007).
55. Wiemels, J.L. et al. History of allergies among adults with glioma and controls. Int. J. Cancer 98, 609-615 (2002).
56. Felini, M.J. et al. Reproductive factors and hormone use, and risk of adult gliomas. Cancer Causes Control 20, 87-96 (2009).
57. Howie, B.N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).
58. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467, 1061-1073 (2010).
59. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906-913 (2007).
60. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559-575 (2007).
61. Patterson, N., Price, A.L. & Reich, D. Population structure and eigenanalysis. PLoS Genet. 2, e190 (2006).
62. Jenkins, R.B. et al. Distinct germline polymorphisms underlie glioma morphologic heterogeneity. Cancer Genet. 204, 13-18 (2011).
63. Pritchard, J.K., Stephens, M. & Donnelly, P. Inference of population structure using multilocus genotype data. Genetics 155, 945-959 (2000).
64. Liu, J.Z. et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat. Genet. 42, 436-440 (2010).
65. Higgins, J.P., Thompson, S.G., Deeks, J.J. & Altman, D.G. Measuring inconsistency in meta-analyses. Br. Med. J. 327, 557-560 (2003).
66. Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: a tool for genome-wide complex-trait analysis. Am. J. Hum. Genet. 88, 76-82 (2011).
67. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat. Genet. 44, 369-375 (2012).
68. Ward, L.D. & Kellis, M. HaploReg: a resource for exploring chromatin states, conservation and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40, D930-D934 (2012).
69. Boyle, A.P. et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 22, 1790-1797 (2012).
70. Ng, S.B. et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461, 272-276 (2009).
71. Roadmap Epigenomics Consortium. Integrative analysis of 111 reference human epigenomes. Nature 518, 317-330 (2015).
72. Pharoah, P.D., Antoniou, A.C., Easton, D.F. & Ponder, B.A. Polygenes, risk prediction and targeted prevention of breast cancer. N. Engl. J. Med. 358, 2796-2803 (2008).
73. Scheurer, M.E. et al. Familial aggregation of glioma: a pooled analysis. Am. J. Epidemiol. 172, 1099-1107 (2010).
74. Danecek, P. et al. The variant call format and VCFtools. Bioinformatics 27, 2156-2158 (2011).
75. Scales, M., Jager, R., Migliorini, G., Houlston, R.S. & Henrion, M.Y. visPIG-a web tool for producing multiregion, multitrack, multiscale plots of genetic data. PLoS One 9, e107497 (2014).
76. Gabriel, S.B. et al. The structure of haplotype blocks in the human genome. Science 296, 2225-2229 (2002).